Menu
2012 Session

Budget Amendments - HB30 (Floor Approved)

View Budget Item
View Budget Item amendments

Exempt Certain Behavioral Health Drugs from Medicaid PDL

Item 307 #11h

Item 307 #11h

First Year - FY2013 Second Year - FY2014
Health And Human Resources
Medical Assistance Services, Department of FY2013 $2,100,000 FY2014 $0 GF
FY2013 $2,100,000 FY2014 $0 NGF

Language
Page 225, line 49, strike "$7,438,749,436" and insert "$7,442,949,436".
Page 229, line 42, after "7." insert "a."
Page 229, line 42, after "shall (i)", insert:
"exempt antidepressant, antianxiety and antipsychotic medications used for the treatment of mental illness from the Medicaid Preferred Drug List program; (ii)
Page 229, line 43, strike "and".
Page 229, line 44, strike "ii" and insert "iii".
Page 229, after line 50, insert:
"b.  The Department of Medical Assistance Services shall report to the Chairmen of the House Appropriations and Senate Finance Committees on the cost and utilization of behavioral health drugs paid for through the Medicaid fee-for-service program,  Medicaid managed care programs and the Medicaid behavioral health administrative services organization.  As part of this report, the Department shall assess the changes in the monthly cost, utilization and availability of these drugs in fiscal year 2013 compared to monthly expenditures and utilization in fiscal year 2012.  The Department shall provide an interim report on November 1, 2012 and a final report on July 1, 2013."


Explanation
(This amendment adds $2.1 million from the general fund and a like amount of matching federal Medicaid funds the first year to continue the current exemption of antidepressant, antianxiety and antipsychotic medications used to treat mental illness from the Medicaid Preferred Drug List (PDL). Language is added for the Department of Medical Assistance Services to report to the General Assembly money committees on the cost and utilization of these drugs paid for through the Medicaid fee-for-service program, in Medicaid managed care programs and in the Medicaid behavioral health administrative services organization and to assess the changes in the cost and availability of these drugs.)